Prochlorperazine for Dizziness: Efficacy and Guidelines

Efficacy for Dizziness

The American Academy of Family Physicians suggests that prochlorperazine can be effective for treating dizziness, particularly when associated with nausea and vomiting, but should not be used as first-line therapy for vertigo of specific causes like BPPV where targeted treatments are more appropriate 1

The American Academy of Family Physicians recommends standard dosing of 5 mg three times daily for acute dizziness, with treatment typically lasting 5-7 days, and for severe symptoms, it can be administered as 25 mg orally or via suppository, with a maximum of three doses per 24 hours 1, 2

The American Academy of Family Physicians notes that potential side effects of prochlorperazine include hypotension, tachycardia, arrhythmias, akathisia, pseudo-parkinsonism, tardive dyskinesia, dystonia, dizziness, dry mouth, constipation, urinary retention, and blurred vision 1, 2, 3
Contraindications for prochlorperazine include CNS depression and use of adrenergic blockers, as stated by the American Academy of Family Physicians 1, 2

The American Academy of Otolaryngology-Head and Neck Surgery recommends against routine use of vestibular suppressant medications, including phenothiazines like prochlorperazine, as primary treatment for BPPV, and instead suggests repositioning maneuvers as the first-line treatment 4, 5
The American Academy of Otolaryngology-Head and Neck Surgery suggests that medications like prochlorperazine are reserved for managing associated symptoms like severe nausea in BPPV patients 4, 5
The American Academy of Family Physicians notes that prochlorperazine can effectively relieve headache pain and associated symptoms as adjunctive therapy for migraine-associated vertigo 1, 2

The American Academy of Otolaryngology-Head and Neck Surgery recommends reassessing patients within 1 month if symptoms persist to confirm resolution or consider alternative diagnoses 5
The Annals of Oncology suggests using lower doses of prochlorperazine in elderly patients or those with hepatic/renal impairment 6
The Annals of Oncology notes that prolonged use of prochlorperazine can lead to QT prolongation 6